NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
Clinical Trials
29 trialsNCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT07342517 2026-03-17
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07284953 2026-03-13
PuraBond
The Royal Wolverhampton Hospitals NHS Trust
Phase NA Withdrawn
NCT04953312 2026-03-12
CALPRO
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT06229392 2026-03-11
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
Rush University Medical Center
Phase 1 Withdrawn
NCT07137390 2026-03-11
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06240390 2026-03-09
Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain
Universidad Europea de Canarias
Phase NA Withdrawn
NCT06292975 2026-03-06
Exercise for Improving Radiotherapy Efficacy in Rectal Cancer
University of Hull
Phase NA Withdrawn
NCT04243473 2026-03-03
Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Withdrawn
NCT07211204 2026-03-03
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
Timser SAPI de CV
Phase NA Withdrawn
NCT03804255 2026-03-02
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting
Eastern Cooperative Oncology Group
Withdrawn
NCT05296135 2026-02-27
PREDAPT-HNSCC2
Cofactor Genomics, Inc.
Withdrawn
NCT07439432 2026-02-27
Stereotactic Guided Biopsy and Cryoablation
Montefiore Medical Center
Phase NA Withdrawn
NCT06796049 2026-02-25
Behavioral Nudge in Colorectal Cancer Screening
NYU Langone Health
Phase NA Withdrawn
NCT05014295 2026-02-24
Patient Recall of Cancer Screening and Diagnosis
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT06297629 2026-02-24
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06522373 2026-02-24
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03905941 2026-02-23
SHK002
University of Virginia
Phase EARLY_PHASE1 Withdrawn
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT06217094 2026-02-18
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
University of Florida
Phase 1 Withdrawn
NCT06868238 2026-02-18
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
University of Florida
Phase 2 Withdrawn
NCT03027986 2026-02-17
PROTOMEN
University Hospital, Rouen
Phase NA Withdrawn
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT05487859 2026-02-17
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
Phase 2 Withdrawn